Table 1 Baseline demographic and ocular characteristics for treatment-naïve patients with CRVO.

From: Effectiveness and safety of ranibizumab in patients with central retinal vein occlusion: results from the real-world, global, LUMINOUS study

Characteristics

Overall

Patients with Year 1 data

Patients without Year 1 data

N = 327a

n = 144b

n = 183c

Mean (SD) age, years

68.9 (13.0)

70.0 (11.88)

67.9 (13.83)

Gender, (%)

  Male

186 (56.9)

74 (51.4)

112 (61.2)

Race, (%)

  White

251 (76.8)

122 (84.7)

129 (70.5)

  Asian

38 (11.6)

9 (6.3)

29 (15.8)

  Native American

2 (0.6)

0

2 (1.1)

  Black

1 (0.3)

0

1 (0.5)

  Other

19 (5.8)

3 (2.1)

16 (8.7)

  Missing

16 (4.9)

10 (6.9)

6 (3.3)

VA

  n

294

144

150

  Mean (SD) VA, ETDRS letters

40.6 (23.9)

40.7 (22.17)

40.6 (25.44)

CRT

  n

224

109

115

  Mean (SD) CRT, µm

551.5 (220)

566.4 (206.29)

537.4 (232.17)

Median time from diagnosis to first treatment, days

21

16.5

23

  1. CRT central retinal thickness, CRVO central retinal vein occlusion, EDTRS early treatment diabetic retinopathy study, n number of patients, SD standard deviation, VA visual acuity
  2. aAll patients who signed the informed consent and had at least a baseline assessment (enroled set).
  3. bPatients included in Year 1 effectiveness analysis who had both baseline and Year 1 data and had remained in the study for at least 365 days (primary treated eye set).
  4. cPatients who have unavailable baseline or Year 1 VA data, or are not included in effectiveness analysis for Year 1 or have been in the study for <365 days (primary treated eye set).
Back to article page